当前位置: X-MOL 学术Nat. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Nature Medicine ( IF 58.7 ) Pub Date : 2020-06-18 , DOI: 10.1038/s41591-020-0973-6
You Lu 1 , Jianxin Xue 1 , Tao Deng 2 , Xiaojuan Zhou 1 , Kun Yu 2 , Lei Deng 3 , Meijuan Huang 1 , Xin Yi 4 , Maozhi Liang 5 , Yu Wang 6 , Haige Shen 6 , Ruizhan Tong 1 , Wenbo Wang 7 , Li Li 1 , Jin Song 4 , Jing Li 4 , Xiaoxing Su 8 , Zhenyu Ding 1 , Youling Gong 1 , Jiang Zhu 1 , Yongsheng Wang 1, 5 , Bingwen Zou 1 , Yan Zhang 1 , Yanying Li 1 , Lin Zhou 1 , Yongmei Liu 1 , Min Yu 1 , Yuqi Wang 4 , Xuanwei Zhang 1 , Limei Yin 1 , Xuefeng Xia 4 , Yong Zeng 2 , Qiao Zhou 9 , Binwu Ying 10 , Chong Chen 11 , Yuquan Wei 11 , Weimin Li 12 , Tony Mok 13
Affiliation  

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

中文翻译:

出版商更正:CRISPR编辑的T细胞在难治性非小细胞肺癌患者中的安全性和可行性。

该文件的修订版已经发布,可以通过文件顶部的链接进行访问。
更新日期:2020-06-18
down
wechat
bug